|
|
Investigation on the mechanism of ginsenoside
Rg3 in treating murine primary mammary tumor |
Hongbo TANG MD,Zirong YE MM,Yuping REN MD,Zhanyong ZHU MD,Yiping WU MD, |
Department of General
Surgery, Tongji Hospital, Tongji Medical College, Huazhong University
of Science and Technology, Wuhan 430030, China; |
|
|
Abstract A murine primary mammary tumor model was established to investigate the treatment with ginsenosides Rg3. The relationship between ginsenosides Rg3 and primary mammary tumor was explored. Mammary tumor was induced by using the 7,12-dimethybenz(a)anthracene (DMBA). Ginsenoside Rg3 was employed for treatment. The incidence of mammary tumor in every group was compared, and the expressions of vascular endothelial growth factor (VEGF) and microvessel density (MVD) were detected by immunohistochemical method. The cell cycle and apoptosis percentage were determined by means of flow cytometry. The incidence of tumor in treatment group was significantly lower than that in control group (60.00% vs 33.33%, P<0.05). The average diameter of mammary tumor was (0.86±0.27) cm in control group and (0.39±0.09) cm in treatment group, with the difference being significant between control and treatment groups (P<0.01). The MVD value was (31.9±5.3) in control group and (20.1±4.9) in treatment group, respectively. There was a significant difference between the two groups (P<0.05). The apoptosis percentage in control group was significantly lower than that in treatment group [(2.47±0.69)% vs (5.67±0.99)%, P<0.05]. Ginsenoside Rg3 can play an antitumor role in primary mammary tumor model by inhibiting angiogenesis, cell cycle progression, and promoting cell apoptosis.
|
Keywords
ginsenoside Rg3
mammary tumor
mice
|
Issue Date: 05 December 2009
|
|
|
Okobia M N, Bunber C H. Epidemiological risk factorsfor mammary tumor- a review. Niger J ClinPract, 2005, 8(1): 35―42
|
|
Baoning Z. Retrospectand Prospect of Clinical research in breast cancer. Zhonghua Yi Xue Za Zhi, 2005, 85(1): 7,8 (in Chinese)
|
|
Yun T K, Lee Y S, Lee Y H, Kim S I, Yun H Y. Anticarcinogenic effect of Panax ginsengC.A. Meyer and identification of active compounds. Korean Med Sci, 2001, 16(Suppl): S6―18
|
|
Shibata S. Chemistryand caner preventing activities of ginseng saponins and some relatedtriterpenoid compounds. Korean Med Sci, 2001, 16(Suppl): 28―37
|
|
Zhang H L, Wang H Q, Yao Z, Hao X S. Study oneffect of ginsenoside Rg3 on immunological recovery after peripheralblood stem cell transplantation in animal experiments. Zhong Hua Fang She Yi Xue Yu Fang Hu Za Zhi, 2005, 10(5): 431―434 (in Chinese)
|
|
Weidner N, Folkmen J, Pozza F, Bevilacqua P, Allred E N, Moore D H, Meli S, Gasparini G. Tumor angiogenesis: a newsignificant and independent prognostic in early-stage breast carcinoma. Natl Cancer Inst, 1992, 84(7): 1875―1887
doi: 10.1093/jnci/84.24.1875
|
|
Zhang Q, Kang X, Zhao W. Antiangiogenic effect of low- dose cyclophosphamide combinedwith ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun, 2006, 342(3): 824―828
doi: 10.1016/j.bbrc.2006.02.044
|
|
Kim H S, Lee E H, Ko S R, Choi K J, Park J H, Im D S. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostatecancer cells. Arch Pharm Res, 2004, 27(4): 429―435
doi: 10.1007/BF02980085
|
|
Keum Y S, Han S S, Chun K S, Park K K, Park J H, Lee S K, Surh Y J. Inhibitory effects of theginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression,NF–kappa B activation and tumor promotion. Mutat Res, 2003, 523―524: 75―85
doi: 10.1016/S0027-5107(02)00323-8
|
|
Huang X B, Hou M, Yi C, Song H B. Anti-angiogeniceffects of low-dose gemcitabine combined with ginsenoside Rg3 on mouseLewis lung carcinoma. Zhong Guo Fei AiZa Zhi, 2006, 9(2): 132―136 (in Chinese)
|
|
Chen J X, Xia J, Liu J W, Cui X Y. Experimentalstudy on apoptosis induced by ginsenoside Rg3 in human MCF-7 breastcancer cell line. Ai Bian Ji Bian Tu Bian, 2005, 17(4): 213―216 (in Chinese)
|
|
Blood C H, Zecter B R. Tumor interaction with thevasculature: angiogenesis and metastasis. Biochem Biophys Acta, 1990, 1032: 89―118
|
|
Basu S, Nagy J A, Pal S, Vasile E, Eckelhoefer I A, Bliss S, Manseau E J, Dasgupta P S, Dvorak H F, Mukhopadhyay D. Theneurotransmitter dopamine inhibits angiogenesis induced by vascularpermeability factor/ vascular endothelial growth factor. Nat Med, 2001, 7(5): 569―574
doi: 10.1038/87895
|
|
Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/ vascular endothelial growth factor,microvascular hyper-permeability and angiogenesis. Am J Pathol, 1995, 146(5): 1029―1032
|
|
Uzzan B, Nicolas P, Cucherat M, Perret G Y. Microvessel density as a prognostic factor in women with breastcancer: a systematic review of the literative and meta-analysis. Cancer Res, 2004, 64(9): 2941―2955
doi: 10.1158/0008-5472.CAN-03-1957
|
|
Fan Z H, Isobe K, Kiuchi K, Nakashima I. Enhancementof nitric oxide production from activated macrophages by a purifiedform of ginsenoside (Rg1). Am J Chin Med, 1995, 23(3,4): 279―287
|
|
Tao X, Tang D. Advances in the study oftumor angiogenesis and anti-angiogenic Chinese herbal drugs. Zhong Yao Cai, 2003, 26(5): 379―381 (in Chinese)
|
|
Kim N D, Kang S Y, Schini V B. Ginsenosides evoke endothelium dependent vascular relaxationin rat aorta. Gen Pharmacol, 1994, 25(6): 1071―1077
doi: 10.1016/0306-3623(94)90121-X
|
|
Shinkai K, Akedo H, Mukai M, Imamura F, Isoai A, Kobayashi M, Kitagawa I. Inhibitionof in vitro tumor cell invasion by ginsenoside Rg3. Jpn J Cancer Res, 1996, 87(4): 357―362
|
|
Radomski M W, Palmer R M, Moncada S. Characterization of the Larginine: nitric oxide pathwayin human platelets. Br J Pharmacol, 1990, 101: 325―328
|
|
Liu W K, Xu S X, Che C T. Anti-proliferative effect of ginseng saponins on humanprostate cancer cellline. Life Sci, 2000, 67(11): 1297―1306
doi: 10.1016/S0024-3205(00)00720-7
|
|
Xin Y, Ni J S, Wang X R, Shi B, Wang Y H, Wu J X. Inhibitory effect of 20(S)-ginsenoside Rg3 on B16 melanoma growth. Lin Chuang Zhong Liu Xue Za Zhi, 2004, 9(6): 604―607 (in Chinese)
|
|
He F. Researchprogress of 20(S)-ginsenoside Rg3 on anti-tumor mechanism. Yi Nan Bing Za Zhi, 2005, 4(5): 315―317 (in Chinese)
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|